Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...

Seven life sciences companies cut at least 346 jobs in Massachusetts between April and June, with some of the layoffs tied to ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Amylyx ...

Sofinnova Investments’ Jim Healy says biotech innovation is thriving but is skeptical about artificial intelligence’s ability ...

Biotech is now the deepest pocket of leadership in the entire Nasdaq. Everyone can see biotech is moving, and the why is ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

A weekly newsletter focusing on the most important news in health and biotech. Founded at the Massachusetts Institute of ...

It has been a banner year for biotech buyouts, and these are two of the prime targets.

David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Launched on June 19, 2006, the First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...